SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Transcatheter Valve Solutions

Transcatheter Valve Solutions

With a commitment to advancing innovative technology to ensure people living with structural heart diseases have safe and effective treatment options, Abbott was the first to develop minimally invasive transcatheter edge-to-edge repair (TEER) therapy for patients with mitral regurgitation (MR) and tricuspid regurgitation (TR), and reimagined the minimally invasive treatment of aortic stenosis.

MitraClip™ TEER Therapy

MitraClip™ Transcatheter Edge-to-Edge Repair (TEER) procedure is a minimally invasive treatment option, uniquely designed for the mitral valve, for select patients with primary or secondary MR. As the first TEER therapy recommended by ACC/AHA1 and ESC/EACTS2-3 guidelines and by ASPC Recommendation,4 MitraClip is the only tailored therapy with over 20 years of clinical experience and more than 200,000 patients treated worldwide,5 allowing physicians to treat more patients with more options.

mitraclip

Navitor™ TAVI System

Advancing the forefront of innovative design, the Navitor™ Transcatheter Aortic Valve Implantation (TAVI) System brings together smart PVL-sealing technology, exceptional single-digit gradients,6 stable deployment, accurate valve placement and uncompromised coronary access to achieve excellent clinical outcomes in patients with severe aortic stenosis who are at high or greater risk for surgery.

portico

Tendyne™ TMVR System

Tendyne™ Transcatheter Mitral Valve Replacement (TMVR) System is first-in-class technology designed to eliminate mitral regurgitation (MR), offering select patients with MR (≥ grade 3), a minimally invasive option for mitral valve replacement. The Tendyne TMVR system provides improvements in heart failure symptoms by consistently reducing MR.

portico

TriClip™ TEER System

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) is a minimally invasive treatment option for patients with symptomatic severe Tricuspid Regurgitation (TR). TriClip TEER offers unmatched stability, precision, and control for the unique challenges of the tricuspid anatomy to achieve sustained, clinically significant improvements in the lives of TR patients.

portico
Manuals & Technical Resources

Manuals & Technical Resources

Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Heidenreich PA, et al. "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association. Joint Committee on Clinical Practice Guidelines." J Am Coll Cardiol. Apr 01,2022. Epublished DOI: 10.1016/j.jacc.2021.12.012.
  2. Vahanian A, Beyersdorf F, Praz F, et al., ESC/EACTS Scientific Document Group, 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 561–632, https://doi.org/10.1093/eurheartj/ehab368
  3. McDonagh TA, Metra M, Adamo M, et al., ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726, https://doi.org/10.1093/eurheartj/ehab368
  4. Yeo KK, Tan JWC, Muller DW, et al. Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation. Eur Cardiol. 2021;16:e25. Published 2021 Jun 1. doi:10.15420/ecr.2021.01
  5. Data on File at Abbott.
  6. Smith, D. One-year clinical trial results with a next-generation aortic transcatheter heart valve. Presented at: EuroPCR conference; May 17-20, 2022.

MAT-2011954 v6.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0